Overview

A Study to Evaluate Efficacy, Tolerability, Pharmacodynamic and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adults With Schizophrenia

Status:
Completed

Trial end date:
2020-12-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether TAK-831 is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.

Phase:

Phase 2

Details

Lead Sponsor:

Neurocrine Biosciences
Takeda

Collaborator:

Takeda